Lysogene

Lysogene is a biotechnology company focused on developing gene therapies for rare inherited diseases. The company was founded in 2010 and is based in Paris, France. Lysogene's research and development efforts are concentrated on neurological and lysosomal storage disorders. Their primary therapeutic approach involves using adeno-associated viral (AAV) vectors to deliver functional genes to affected cells, aiming to correct the underlying genetic defect.

The company's pipeline includes programs targeting conditions such as mucopolysaccharidoses (MPS) and Huntington's disease. Lysogene emphasizes the potential of gene therapy to offer a one-time treatment option for patients with these devastating conditions, which often have limited or no effective therapies. Their preclinical and clinical studies aim to demonstrate the safety and efficacy of their gene therapy candidates. Lysogene collaborates with academic institutions and other research organizations to advance its scientific understanding and therapeutic development. The company's work is driven by the goal of addressing unmet medical needs and improving the lives of patients affected by rare genetic disorders.